New once-daily formulation for trospium in overactive bladder

International Journal of Clinical Practice

Volumn 64, Issue 11, 2010, Pages 1535-1540

  Chapple, C ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; CYTOCHROME P450; DARIFENACIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PROPIVERINE; SANTURA; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ALERTNESS; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER PRESSURE; BLOOD BRAIN BARRIER; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CYSTOMETRY; DATA ANALYSIS; DAYTIME SOMNOLENCE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRY EYE; DYSPEPSIA; DYSPHAGIA; FIRST PASS EFFECT; HUMAN; INSOMNIA; LIVER METABOLISM; LOW DRUG DOSE; LOWER ABDOMINAL PAIN; MICTURITION; NAUSEA; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RESIDUAL URINE; REVIEW; SIDE EFFECT; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

DRUG ADMINISTRATION SCHEDULE; HUMANS; META-ANALYSIS AS TOPIC; MUSCARINIC ANTAGONISTS; NORTROPANES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 77956790684     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02493.x     Document Type: Review

References (32)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neuourol Urodyn 2002 21 : 167 78.
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 6.
3. Ouslander JG. Management of overactive bladder. N Engl J Med 2004 350 : 786 98.
4. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001 21 : 243 8.
5. Staskin DR. Trospium chloride: distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am 2006 33 : 465 73.
6. Silver N, Sandage B, Sabounjian L, Schwiderski U, Shipley J, Harnett M. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice daily trospium chloride 20 mg in healthy adults. J Clin Pharmacol 2010 50 : 143 50.
7. Sandage B, Najarian N, Lasseter K. The effect of hepatic disease on the pharmacokinetics of trospium chloride. Poster Presentation ICS and IUGA Joint Meeting Paris 2004. Abstract 584.
8. Trospium chloride PI. Available at http://www.medicines.org.uk/EMC/ medicine/22236/SPC/Regurin+XL+60mg/ (accessed 23 August 2010).
9. Schladitz-Keil G, Spahn H, Mutschler E. Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. Arzneimittelforschung 1986 36 : 984 7.
10. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006 148 : 565 78.
11. Kay GG, Abou-Donia MB, Messer WS Jr., Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005 53 : 2195 201.
12. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008 62 : 1792 800.
13. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994 47 : 337 43.
14. Herberg KW. General and traffic safety and the effects of incontinence medication: new studies on the safety potential of urological anticholinergics. Med Welt 1999 50 : 217 22.
15. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 2004 5 : 423 6.
16. Halaska M, Ralph G, Wiedemann A et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003 20 : 392 9.
17. Zinner N, Gittelman M, Harris R, Susset J, Kanellos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004 171 : 2311 5.
18. Staskin D, Sand P, Zinner N, Dmochowski R. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase three trial. J Urol 2007 178 : 978 84.
19. Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008 71 : 449 54.
20. Cardozo L, Chapple CR, Toozs-Hobson P et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000 85 : 659 64.
21. Staskin DR, Cardozo L. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. Int J Clin Pract 2009 63 : 973 6.
22. Dallosso HM, McGrother CW, Matthews RJ et al. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int 2003 92 : 69 77.
23. Dallosso HM, Matthews RJ, McGrother CW et al. The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men. Public Health Nutr 2004 7 : 885 91.
24. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001 57 : 414 21.
25. Staskin D, Kay G, Goldman HB, Ling J, Bashi K, Oefelein MG. Sanctura XR a muscarinic antagonist resists transport (SMART) across the blood-brain barrier (BBB): a prospective, neurocognitive, biodistribution and pharmacokinetic study of extended release trospium chloride (TrCl). J Urol 2010 183 : 4 Supplement, Abstract 1501.
26. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008 54 : 543 62.
27. Haab F, Cardozo L, Chapple C, Ridder AM. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005 47 : 376 84.
28. Kreder K, Mayne C, Jonas U. Long term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002 41 : 588 95.
29. Haab F, Corcos J, Siami P et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006 98 : 1025 32.
30. Shay FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Managed Care 2005 11 : S121 9.
31. Brostrom S, Hallas J. Persistence with antimuscarinic drug use. Eur J Clin Pharmacol 2008 65 : 309 14.
32. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor M. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU int 2005 97 : 400 3.